Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...

Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...

Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...

Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...

Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the ...

The Shield test will be reimbursed at the amount of $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1, 2025. During the initial ADLT period, Guardant Health ...

(RTTNews) - Guardant Health, Inc. (GH) Tuesday announced that the Centers for Medicare & Medicaid Services or CMS has granted Advanced Diagnostic Laboratory Test or ADLT status to its Shield blood ...

Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) ...